Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice

References

1. Araullo-Cruz T, Ho , Armstrong J. 1978; Protective effect of early serum from mice after cytomegalovirus infection. Infection and Immunity 21:3840–842
   [Google Scholar]
2. Bosma G, Custer R, Bosma MJ. 1983; A severe combined immunodeficiency mutation in the mouse. Nature 301:527–530
   [Google Scholar]
3. Britt WJ, Pass RF, Stagno S, Alford CA. 1991; Pediatric cytomegalovirus infection. Transplantation Proceedings 23:115–117
   [Google Scholar]
4. Emanuel D. 1990; Treatment of cytomegalovirus disease. Seminars in Hematology 1:22–27
   [Google Scholar]
5. Erice A, Sunwe C, Biron KK, Stanat SC, Balfour HH, Jordan MC. 1989; Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised Patients.. New England Journal of Medicine 320:289–293
   [Google Scholar]
6. Ikeda S, Kumazawa Y, Nishimura C, Nakatsuka M, Homma JY, Kiso M, Hasegawa A. 1988a; Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups. Antiviral Research 10:167–178
   [Google Scholar]
7. Ikeda S, Nishimura C, Nakatsuka M, Yuzuru Homma J, Kiso M, Hasegawa A. 1988b; Antiviral and immunomodulating activities of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-60. Antiviral Research 9:37–46
   [Google Scholar]
8. Ikeda S, Tominaga T, Nishimura C, Homma JY, Kiso M, Hasegawa A. 1989; Antiherpes activity of chemically synthesized lipid A-subunit analogue GLA-60 in immunosuppressed mice. Antiviral Research 11:173–180
   [Google Scholar]
9. Ikeda S, Kaneko M, Nishiya S, Nishimura C. 1990; Restoration of hematopoietic activity by lipid A analogue GLA-60 in cyclophosphamide-treated immunosuppressed mice. Journal of Clinical Laboratory Immunology 32:93–93
   [Google Scholar]
10. Ikeda S, Neyts J, Matsuura M, Kiso M, Hasegawa A, Nishimura C, De Clercq E. 1993; Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice.. Journal of Medical Virology 40:222–227
    [Google Scholar]
11. Janeway CA. 1989; A primitive immune system. Nature 341:108–108
    [Google Scholar]
12. Kiso M, Tanaka S, Fujita M, Fujishima Y, Ogawa Y, Ishida H, Hasegawa A. 1987; Synthesis of the optically active 4-O-phosphono-d-glucosamine derivatives related to the nonreducing-sugar subunit of bacterial lipid A.. Carbohydrate Research 162:127–140
    [Google Scholar]
13. Kumazawa Y, Nakatsuka M, Takimoto H, Furuya T, Nagumo T, Yamamoto A, Homma Y, Inada K, Yoshida M, Kiso M. 1988; Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity.. Infection and Immunity 56:149–155
    [Google Scholar]
14. Manischewitz JE, Quinnan GV. 1980; Antivirus antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection.. Infection and Immunity 29:1050–1054
    [Google Scholar]
15. Matsuura M, Kojima Y, Homma JY, Kubota Y, Shibukawa N, Shibata M, Inage M, Kusumoto S, Shiba T. 1983; Interferon-inducing, pyrogenic and proclotting enzyme of horseshoe crab activation activities of chemically synthesized lipid A analogues.. European Journal of Biochemistry 137:639–642
    [Google Scholar]
16. Morahan PS. 1984; Interactions of herpesviruses with mononuclear phagocytes.. In Immunology of Herpes Simplex Virus InfectionEdited by Rouse BT, Lopez C. Boca Raton: CRC Press.; pp 71–89
    [Google Scholar]
17. Nakatsuka M, Kumazawa Y, Matsuura M, Homma JY, Kiso M, Hasegawa A. 1989; Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of N- and 3-O-linked acyl groups in derivatives.. International Journal of Immunopharmacology 11:349–358
    [Google Scholar]
18. Nakatsuka M, Kumazawa Y, Homma JY, Kiso M, Hasegawa A. 1991; Inhibition in mice of experimental metastasis of B 16 melanoma by the synthetic lipid A-subunit analogue GLA-60.. International Journal of Immunopharmacology 13:11–19
    [Google Scholar]
19. Neyts J, Balzarini J, Naesens L, de Clercq E. 1992; Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.. Journal of Medical Virology 37:67–71
    [Google Scholar]
20. Quinnan GV, Manischewitz JE. 1979; The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection.. Journal of Experimental Medicine 150:1549–1554
    [Google Scholar]
21. Rubin RH. 1990; Impact of Cytomegalovirus Infection on Organ Transplant Recipients.. Reviews of Infectious Diseases 12, Supplement 7:754–766
    [Google Scholar]
22. Saiki I, Maeda H, Murata J, Yamamoto N, Kiso M, Hasegawa A, Azuma I. 1989; Antimetastatic effect of endogenous tumor necrosis factor induced by the treatment of recombinant interferon γ followed by an analogue (GLA-60) to synthetic lipid A subunit. Cancer Immunology Immunotherapy 30:151–157
    [Google Scholar]
23. Saiki I, Maeda M, Murata J, Takahashi T, Sekiguchi S, Kiso M, Hasegawa A, Azuma I. 1990; Production of interleukin 1 from human monocytes stimulated by synthetic lipid A subunit analogues.. International Journal of Immunopharmacology 12:297–305
    [Google Scholar]
24. Selgrade MK, Huang YS, Graham JA, Huang CH, Hu PC. 1983; Humoral antibody response to individual viral proteins after murine cytomegalovirus infection. Journal of Immunology 131:3032–3035
    [Google Scholar]
25. Shanley JD, Jordan MC, Stevens JG. 1981; Modification by Adoptive Humoral Immunity of Murine Cytomegalovirus Infection. Journal of Infectious Diseases 143:231–237
    [Google Scholar]
26. Shellam GR, Allan JE, Papadimitriou JM, Bancroft GJ. 1981; Increased susceptibility to cytomegalovirus infection in beige mutant mice.. Proceedings of the National Academy of Sciences 78:5104–5108
    [Google Scholar]
27. Shellam GR, Flexman JP, Farrell HE, Papadimitriou JM. 1985; The Genetic Background Modulates the Effect of the Beige Gene on Susceptibility to Cytomegalovirus Infection in Mice. Scandinavian Journal of Immunology 22:147–155
    [Google Scholar]
28. Staczeik J. 1990; Animal cytomegaloviruses.. Microbiological Reviews 54:247–265
    [Google Scholar]
29. Stagno S, Pass RF, Dworsky ME, Henderson RE, Moore EG, Walton PD, Alford CD. 1982 New England Journal of Medicine Congenital cytomegalovirus infections: the relative importance of primary and recurrent maternal infections.. 306:945–949
    [Google Scholar]
30. Starr SE, Allison AC. 1977; Role of T lymphocytes in recovery from murine cytomegalovirus infection.. Infection and Immunity 17:458–462
    [Google Scholar]
31. Tyms AS, Taylor DL, Parkin JM. 1989; Cytomegalovirus and the acquired immunodeficiency syndrome. Journal of Antimicrobial Chemotherapy 23:89–105
    [Google Scholar]
32. Verheyden JPH. 1988; Evolution of Therapy for Cytomegalovirus Infection.. Reviews of Infectious Diseases 10, Supplement 3:5477–5489
    [Google Scholar]
33. Welsh RM, Brubaker JO, Vargas-Cortes M, O'Donnell CL. 1991; Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function.. Journal of Experimental Medicine 173:1053–1063
    [Google Scholar]
34. Winston DJ, Ho WG, Champlin RE. 1990; Cytomegalovirus Infections After Allogeneic Bone Marrow Transplantation. Reviews of Infectious Diseases 12, Supplement 7:776–791
    [Google Scholar]